EXL01 clinical trials

Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma

This study looks at adding a special bacteria (EXL01) to standard immunotherapy for advanced liver cancer (hepatocellular carcinoma). The goal is to help treatment work better for patients whose cancer hasn't responded well to initial immunotherapy.